Skip to main content

Table 1 Clinical and biologic characteristics of the patients in two cohorts

From: Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas

Variables

Training cohort (n = 115)

Validation cohort (n = 58)

P-value

Basic results

 Age, years

54 (43.0, 65.0)

52 (45.8, 61.2)

0.611

 Sex (%)

  Female

35 (30.4)

19 (32.8)

0.755

  Male

80 (69.6)

39 (67.2)

 Subtype composition

  ENKTL

40 (34.8)

24 (41.4)

0.037

  PTCL-NOS

32 (27.8)

14 (24.1)

  AITL

25 (21.7)

4 (6.9)

  ALCL

8 (7.0)

11 (19.0)

  EATCL

6 (5.2)

2 (3.4)

  MF/SPTCL

4 (3.5)

3 (5.2)

 ECOG score (%)

  < 2

62 (53.9)

38 (65.5)

0.145

  ≥ 2

53 (46.1)

20 (34.5)

 BM involvement (%)

  Absence

86 (74.8)

47 (81.0)

0.357

  Presence

29 (25.2)

11 (19.0)

 Extranodal sites (%)

  < 2

61 (53.0)

32 (55.2)

0.791

  ≥ 2

54 (47.0)

26 (44.8)

 Ann Arbor stage (%)

  I/II

44 (38.3)

25 (43.1)

0.539

  III/IV

71 (61.7)

33 (56.9)

 B symptoms (%)

  Absence

41 (35.7)

27 (46.6)

0.166

  Presence

74 (64.3)

31 (53.4)

Serological results

 LDH, U/L

243.0 (183.6, 388.0)

224.3 (178.9, 320.6)

0.433

 Β2-MG, mg/L

3.0 (2.2, 3.8)

2.8 (2.2, 3.6)

0.424

 TC, mmol/L

4.0 (3.2, 4.7)

4.1 (3.5, 5.1)

0.087

 HDL-C, mmol/L

1.0 (0.8, 1.2)

1.1 (0.9, 1.3)

0.041

 TG, mmol/L

1.3 (1.0,1.7)

1.2 (0.8,1.8)

0.375

Clinical scoring systems

 IPI (%)

  Low risk

45 (39.1)

24 (41.4)

0.819

  Low-intermediate risk

13 (11.3)

9 (15.5)

  Intermediate-high risk

25 (21.8)

11 (19.0)

  High risk

32 (27.8)

14 (24.1)

Treatment

 Therapy (%)

  CT alone

60 (52.2)

17 (29.3)

0.014

  RT alone

8 (6.9)

4 (6.9)

  CT + RT

18 (15.7)

13 (22.4)

  CT + HDACi

21 (18.3)

22 (37.9)

  CT + HSCT

8 (6.9)

2 (3.5)

Outcomes

 Therapeutic response (%)

  CR/PR

30 (26.1)

24 (41.4)

0.040

  SD/PD

85 (73.9)

34 (58.6)

  Death (%)

67 (58.3)

16 (27.6)

0.000

  Median OS

21.0 (9.0, 55.0)

13.5 (5.4, 17.0)

0.000

  Progression and NRM (%)

78 (67.8)

26 (44.8)

0.004

  Median PFS

12.0 (3.5, 41.0)

9.8 (3.9, 15.6)

0.038

  1. ENKTL extranodal NK/T-cell lymphoma, PTCL-NOS peripheral T-cell lymphoma, not otherwise specified, AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, EATCL enteropathy-associated T-cell lymphoma, MF mycosis fungoides, SPTCL subcutaneous panniculitis-like T-cell lymphoma, ECOG Eastern Cooperative Oncology Group, BM bone marrow, LDH lactate dehydrogenase, β2-MG beta-2 microglobulin, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, IPI International Prognostic Index, CT chemotherapy, RT radiotherapy, HDACi histone deaceylase inhibitor, HSCT hematopoietic stem cell transplantation, CR complete response, PR partial response, SD stable disease, PD progressive disease, OS overall survival, NRM non-relapse mortality, PFS progression-free survival